Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 84 publications
Reassessing Choice Probability: What 59 Macaque Studies Tell Us About Decision-Related Activity in Visual Cortex.
Journal: bioRxiv : the preprint server for biology
Published: June 22, 2026
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 31, 2026
Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: March 18, 2026
Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma-associated sinonasal squamous cell carcinoma.
Journal: NPJ precision oncology
Published: January 10, 2026
Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 24, 2025
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.
Journal: Nature communications
Published: September 26, 2025
Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
Journal: Oral oncology
Published: July 28, 2025
Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer.
Journal: The New England journal of medicine
Published: June 18, 2025
Functional Localization of Visual Motion Area FST in Humans.
Journal: Imaging neuroscience (Cambridge, Mass.)
Published: June 13, 2025
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.
Journal: Future oncology (London, England)
Published: June 13, 2025
Last Updated: 09/26/2026